AMENDMENTS TO THE CLAIMS

Claims

1. **(Original)** A pharmaceutical preparation comprising a synergistic combination of abacavir and alovudine and a pharmaceutical carrier therefor.

2. **(Original)** A preparation according to claim 1 wherein the alovudine is present in an amount of 1-10 mg per unit dose.

3. **(Original)** A preparation according to claim 2 wherein the alovudine is present in an amount of 0.5-7.5 mg per unit dose.

4. **(Original)** A preparation according to claim 3 wherein the alovudine is present in an amount of 0.5-5 mg per unit dose.

5. **(Original)** A preparation according to claim 1, wherein the abacavir is present in an amount of 200-800 mg per unit dose.

6. **(Original)** A preparation according to claim 5, wherein the abacavir is present in an amount of 300-500 mg per unit dose.

7. **(Original)** A preparation according to claim 1, wherein the alovudine and abacavir are present in a weight ratio corresponding to their respective ED50.

8. **(Previously Presented)** A preparation according to claim 1,

wherein the alovudine and abacavir are present in the ratio 1-10:200-800.

9. **(Original)** A patient pack comprising alovudine and/or abacavir and an information insert containing directions on the use of both alovudine and abacavir together in combination.

10. **(Currently Amended)** A method for the treatment of multiresistant HIV in a patient which comprises administering to said patient an effective amount of a synergistic combination of abacavir and alovudine.

11. **(Previously Presented)** The method of claim 10, wherein said administration comprises simultaneous, combined or sequential administration of alovudine and abacavir.

12. (**Currently Amended**) The method of claim ~~9~~10, wherein the administration comprises administration of the patient pack of claim 9.